Novartis opens new global data center for the Americas at its Alcon eye care division headquarters in Fort Worth, Texas, USA
Oct 02, 2015
One of four primary Novartis data centers the 37,000 square-foot facility in Fort Worth will support Novartis’ data center host applications
Environmentally sustainable facility meets and exceeds all LEED Silver and ASHRAE Energy Standards, for reduced energy and water consumption
New facility further reinforces Novartis’ commitment to the Fort Worth community in which Alcon has been headquartered for more than 70 years
Fort Worth, Texas, USA, September 29, 2015– Novartis today opened its newest global data center, consolidating multiple locations across the Americas, making it now one of four Novartis data centers globally. The new data center is located at the headquarters of Novartis' eye care division, Alcon, located in Fort Worth, Texas, USA. Global data centers for Novartis are also located in Basel, Switzerland; East Hanover, New Jersey; and Stein, Switzerland.
"After a thorough evaluation of several global sites, Fort Worth, Texas, offered Novartis the most ideal location for this new center," said Rob James, Novartis CIO. "We thank the City of Fort Worth for their collaboration in helping this center come to fruition and are pleased to establish the center in the community where Alcon is headquartered." Alcon, the global leader in eye care, currently employs approximately 4,400 employees in Fort Worth and 25,000 worldwide.
Novartis, a global healthcare company based in Basel, Switzerland, is recognized as one of the world's most sustainable companies, with a commitment to reducing emissions, and limiting energy and water consumption across its campuses globally. As an environmentally sustainable building, the $53M USD Data Center exceeds all Leadership in Energy and Environmental Design (LEED) Silver and American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE) standards, and will have the following features:
Latest cooling technology for energy efficient use in Texas climate conditions
Temperature-controlled raised flooring for lower energy consumption
Free air cooling when below 70 degrees and proper humidity
Intelligent low-voltage LED lighting
Solar PV panel system to provide 100Kw power for administrative areas
Storm water collection and rain harvesting
Electrical component redundancy to ensure uninterrupted continuity should a component or power source fail
"Novartis is committed to achieving LEED Silver and ASHRAE Energy Standards throughout its campuses worldwide. Our commitment to environmental responsibility is good for the planet and our business, and importantly, the Fort Worth community," said Scott Owen Mason, CTO, Novartis.
In addition to its environmentally friendly features, the facility is engineered to be continually operational during routine maintenance or extreme weather conditions, including tornados. It is designed to industry standards of 99.982 percent reliability, equaling downtime of no more than 95 minutes per year.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.
Melissa Conger Alcon Global Communications +1 817 302 5759 (direct) +1 214 924 4761 (mobile) [email protected] |Uncategorized|9/29/2015 12:00:00 AM|Alcon|Y 380|Alcon voluntarily recalls high-cylinder intraocular lenses within the AcrySof® Toric line sold in Japan|
Alcon voluntarily recalls high-cylinder intraocular lenses within the AcrySof® Toric line sold in Japan
Voluntary recall does not affect Alcon intraocular lenses sold outside of Japan
Fort Worth, Texas, USA - October 2, 2015– Alcon, the global leader in eye care and a division of Novartis, has elected to voluntarily recall high-cylinder intraocular lenses (IOLs) within the AcrySof® Toric line in Japan, following a voluntary recall of its ReSTOR® and ReSTOR® Toric multifocal IOLs in Japan in April 2015. This voluntary recall does not affect any IOLs outside of Japan, nor does it affect Alcon’s monofocal and low-cylinder toric IOLs sold in Japan.
Alcon decided to voluntarily recall its high-cylinder lenses within the AcrySof Toric line in Japan in the interest of patient safety based on an increased number of cases of post-operative inflammation reported following cataract surgery in various clinics in Japan. Alcon is working with clinics in Japan to ensure affected patients are being treated and monitored. No cases of permanent vision loss have been reported.
The manufacturing process for Alcon IOLs manufactured for Japan differs from that used to manufacture IOLs for the rest of the world. Specifically, all IOLs manufactured for Japan undergo a different curing process compared to IOLs manufactured for other markets. As a result, the IOLs manufactured for Japan have different surface properties.
Alcon has conducted a thorough investigation with the help of leading experts in ophthalmology. The investigation has determined that the increase in cases of post-operative inflammation in Japan is correlated to a combination of the unique surface properties of the Japan IOLs and common processing steps that are used only for AcrySof ReSTOR, ReSTOR Toric, and high-cylinder Toric IOLs (SNA6T6-SNA6T9). Alcon has already identified and is implementing process improvements to prevent recurrence of this issue.
No other Alcon IOLs sold in Japan or any IOLs available throughout the rest of the world are affected by this expanded voluntary recall. Alcon is communicating with relevant regulatory authorities globally, including Japan regulatory authorities (MHLW and PMDA) as well as the U.S. Food and Drug Administration (FDA) regarding this expanded market action in Japan and our proposed manufacturing process improvements.
About Alcon Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people see better. Alcon’s three businesses, Surgical, Pharmaceutical and Vision Care, offer the widest spectrum of eye care products in the world. Alcon is a division of the Novartis Group, with pro-forma sales of USD 10.8 billion in 2014. Headquartered in Fort Worth, Texas, USA, Alcon has more than 25,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.